Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
GENEART Receives European Patent for Selective Evolution of Proteins
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GENEART AG informs about patent EP 1913140 titled "Verfahren für die kontinuierliche, zielgerichtete Evolution von Proteinen in vitro" ("Method for carrying out the selective evolution of proteins in vitro") being granted by the European Patent Office.
The patent protects a procedure for the selective identification of improved protein variants (so-called evolution) in Austria, Belgium, Switzerland, Spain, France, the United Kingdom, Italy, Luxemburg, the Netherlands, Sweden and Germany. The German patent of this family of patents had been granted as early as 2007. An application for a comparable protection for North America has been filed under the international patent process.
The patent constitutes the basis for a proprietary technology platform, which allows to improve the efficiency and activity of protein-based therapeutics, vaccines and industrial enzymes.
The technology relies on a continuous one-step process where the generation and screening of protein variants run virtually simultaneously. Therefore, this procedure increases the probability of identifying the ideal protein variant, for example a strong-binding antibody for cancer therapy.
"We have reached another milestone for the extension of our proprietary technology portfolio in the field of Gene Evolution by being granted the European patent. It is our stated goal to not only offer our customers gene variants and gene libraries for screening experiments but, with the successful completion of this project, to also deliver the improved protein over the mid-term", explained Prof. Dr. Ralf Wagner, CEO of GENEART AG.
The patent protects a procedure for the selective identification of improved protein variants (so-called evolution) in Austria, Belgium, Switzerland, Spain, France, the United Kingdom, Italy, Luxemburg, the Netherlands, Sweden and Germany. The German patent of this family of patents had been granted as early as 2007. An application for a comparable protection for North America has been filed under the international patent process.
The patent constitutes the basis for a proprietary technology platform, which allows to improve the efficiency and activity of protein-based therapeutics, vaccines and industrial enzymes.
The technology relies on a continuous one-step process where the generation and screening of protein variants run virtually simultaneously. Therefore, this procedure increases the probability of identifying the ideal protein variant, for example a strong-binding antibody for cancer therapy.
"We have reached another milestone for the extension of our proprietary technology portfolio in the field of Gene Evolution by being granted the European patent. It is our stated goal to not only offer our customers gene variants and gene libraries for screening experiments but, with the successful completion of this project, to also deliver the improved protein over the mid-term", explained Prof. Dr. Ralf Wagner, CEO of GENEART AG.
